Sign In
Buy GTHX
$7.15
+0 (+0%)
At Close: Dec 16, 2024
G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
10:30am, Thursday, 04'th Apr 2024
RESEARCH TRIANGLE PARK, N.C., April 04, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1's Chief Executive Officer Jack Baile
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:20pm, Monday, 01'st Apr 2024
RESEARCH TRIANGLE PARK, N.C., April 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exerci
Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape
05:51pm, Friday, 22'nd Mar 2024
G1 Therapeutics is a biopharmaceutical company that develops and commercializes advanced oncology treatments. Its flagship product, Cosela, is an FDA-approved drug for reducing chemotherapy side effec
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:20pm, Friday, 01'st Mar 2024
RESEARCH TRIANGLE PARK, N.C., March 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exerci
G1 Therapeutics, Inc. (GTHX) Q4 2023 Earnings Call Transcript
02:45pm, Wednesday, 28'th Feb 2024
G1 Therapeutics, Inc. (GTHX) Q4 2023 Earnings Call Transcript
G1 Therapeutics (GTHX) Reports Q4 Loss, Tops Revenue Estimates
08:41am, Wednesday, 28'th Feb 2024
G1 Therapeutics (GTHX) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.73 per share a year ago.
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
06:30am, Wednesday, 28'th Feb 2024
- Achieved $46.3 Million in Net Revenue from Sales of COSELA® (trilaciclib) for Full Year 2023, Representing 48% Growth Over 2022; Provided 2024 Net COSELA Revenue Guidance of $60 to $70 Million - -
G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
08:30am, Tuesday, 27'th Feb 2024
RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1's Chief Executive Officer Jack Bailey
G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024
08:30am, Thursday, 15'th Feb 2024
RESEARCH TRIANGLE PARK, N.C., Feb. 15, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financia
Why Is G1 Therapeutics (GTHX) Stock Down 45% Today?
08:15am, Tuesday, 13'th Feb 2024
G1 Therapeutics (NASDAQ: GTHX ) stock is falling hard on Tuesday after the biopharmaceutical company provided an interim update on a Phase 3 clinical trial of trilaciclib as a breast cancer treatmen
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent DMC
G1 Therapeutics: New Financials And Big Data Readout Alert
07:55am, Tuesday, 09'th Jan 2024
G1 Therapeutics has provided pipeline updates, including encouraging preliminary overall survival data from a phase 2 study of trilaciclib in combination with sacituzumab govitecan for advanced triple
G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference
06:45am, Monday, 08'th Jan 2024
- Initial Data from the Ongoing Phase 2 Trial in Combination with the Antibody-Drug Conjugate (ADC) Sacituzumab Govitecan (SG) Suggest a Potentially Meaningful Improvement in Overall Survival (OS) for
Best Penny Stocks To Buy? 4 To Watch With Big News This Week
02:48pm, Wednesday, 06'th Dec 2023
Penny stocks, securities with share prices under $5, offer investors a chance at exponential returns with little upfront investment. However, investing wisely in penny stocks requires research as thei
G1 Therapeutics, Inc. (GTHX) Q3 2023 Earnings Call Transcript
12:25pm, Wednesday, 01'st Nov 2023
G1 Therapeutics, Inc. (NASDAQ:GTHX ) Q3 2023 Earnings Conference Call November 1, 2023 8:30 AM ET Company Participants Will Roberts – Vice President-Communications Jack Bailey – Chief Executive Of
